Investment Thesis
Encompass Health demonstrates solid revenue growth and exceptional free cash flow generation, but fundamental weakness in earnings growth (0.3% vs. 10.5% revenue growth) indicates significant margin compression and operational headwinds. High leverage (1.0x D/E) combined with poor returns on capital (ROE 7.7%, ROA 2.7%) creates financial risk that offsets positive cash flow characteristics.
Strengths
- Strong revenue growth of 10.5% YoY in healthcare services sector
- Excellent free cash flow generation ($272.2M, 17.2% FCF margin) demonstrates underlying cash generation capacity
- Healthy operating margin of 18.2% provides solid operational foundation
- Adequate debt servicing with 8.2x interest coverage ratio
Risks
- Severe earnings growth deceleration: net income +0.3% vs. revenue +10.5% signals substantial margin compression and operational inefficiency
- Critically low returns on capital: ROE 7.7% and ROA 2.7% indicate poor efficiency in deploying the asset base
- High leverage (1.0x debt-to-equity) with concentrated debt position ($2.5B long-term debt) and low cash buffer ($110.5M) creates financial fragility
- EPS growth (24.2%) driven primarily by share buybacks rather than underlying earnings growth, masking fundamental weakness
Key Metrics to Watch
- Net income growth trend convergence with revenue growth to assess margin stabilization
- Operating leverage and cost structure changes as percentage of revenue
- Return on equity and assets improvement trajectory
- Debt reduction pace and cash position strengthening
- Free cash flow conversion sustainability and capital allocation discipline
Financial Metrics
Revenue
1.6B
Net Income
194.5M
EPS (Diluted)
$1.93
Free Cash Flow
272.2M
Total Assets
7.3B
Cash
110.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
18.2%
Net Margin
12.3%
ROE
7.7%
ROA
2.7%
FCF Margin
17.2%
Balance Sheet & Liquidity
Current Ratio
1.17x
Quick Ratio
1.17x
Debt/Equity
1.00x
Debt/Assets
54.0%
Interest Coverage
8.20x
Long-term Debt
2.5B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T17:30:51.649126 |
Data as of: 2026-03-31 |
Powered by Claude AI